Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Zosano Pharma Corporation ZSANQ

Healthcare Biotechnology
Zosano Pharma Corp is registered with the U.S. Security and Exchange Commission and incorporated in the state of Delaware. Zosano Pharma Corp is primarely in the business of pharmaceutical preparations. For financial reporting, their fiscal year ends on December 31st. This page includes all SEC registration details as well as a list of all documents (S-1, Prospectus, Current Reports, 8-K, 10K... see more

Recent & Breaking News (EXPM:ZSANQ)

Zosano Pharma Files Voluntary Petition for Relief Under Chapter 11

GlobeNewswire June 2, 2022

Zosano Pharma Reports First Quarter 2022 Financial Results

GlobeNewswire May 13, 2022

Zosano Pharma Provides Corporate Update

GlobeNewswire April 29, 2022

Zosano Pharma Announces Reverse Stock Split Effective Today

GlobeNewswire April 11, 2022

Zosano Pharma Reports Fourth Quarter and Fiscal Year 2021 Financial Results

GlobeNewswire March 17, 2022

Zosano Pharma Announces Pricing of $15.4 Million Public Offering of Common Stock and Warrants

GlobeNewswire February 8, 2022

Zosano Pharma Announces Proposed Public Offering of Common Stock and Warrants

GlobeNewswire February 8, 2022

CORRECTION - Zosano Pharma Announces Publication of Clinical Data Demonstrating Comparable Immunogenicity of a Trivalent Influenza Vaccine Formulated on its Transdermal Microneedle System Versus an Intramuscular Injection of the Vaccine at a Higher Dose

GlobeNewswire January 5, 2022

Zosano Pharma Announces Publication of Clinical Data Demonstrating Comparable Immunogenicity of a Trivalent Influenza Vaccine Formulated on its Transdermal Microneedle System Versus an Intramuscular Injection of the Vaccine at a Higher Dose

GlobeNewswire January 5, 2022

Zosano Pharma Announces Changes to Board of Directors; Appoints Cross Functional Business Executive Elaine M. Yang

GlobeNewswire December 13, 2021

Zosano Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire November 29, 2021

Zosano Pharma Announces the Successful Formulation of a COVID-19 Vaccine Candidate on its Microneedle Patch System

GlobeNewswire November 17, 2021

Zosano Pharma Reports Third Quarter 2021 Financial Results

GlobeNewswire November 10, 2021

Zosano Pharma Granted Type C Meeting with FDA Regarding NDA Resubmission for M207 Following Preliminary Top-Line Pharmacokinetic Study Results

GlobeNewswire October 4, 2021

Zosano Pharma to Present at the H.C. Wainwright Virtual Global Investment Conference

GlobeNewswire September 2, 2021

Zosano Pharma Reports Second Quarter 2021 Financial Results

GlobeNewswire August 10, 2021

Zosano Pharma Announces Issuance of U.S. Patent for Method of Rapidly Achieving Therapeutic Levels with M207 for the Acute Treatment of Migraine

GlobeNewswire July 20, 2021

Zosano Pharma Announces Publication of Clinical Data Regarding the Long-term use of Qtrypta(TM) for the Treatment of Acute Migraine in The Journal of Headache and Pain

GlobeNewswire May 26, 2021

Zosano Appoints Industry Veteran, Kathy McGee, to its Board of Directors

GlobeNewswire May 25, 2021

Zosano Pharma Reports First Quarter 2021 Financial Results

GlobeNewswire May 12, 2021